
FDA Clears Autobahn’s IND for Phase 2 Trial of ABX-002 in Bipolar Depression
Autobahn Therapeutics, a biotech company focused on developing restorative treatments for neuropsychiatric and neuroimmunologic disorders, announced the clearance of an investigational new drug (IND) ...

Aldeyra Therapeutics Completes Enrollment for Phase 2 trial of ADX-2191 for Treatment of Retinitis Pigmentosa
Aldeyra Therapeutics, Inc. has announced the completion of the enrollment process for the Phase 2 Clinical Trial of ADX-2191 (methotrexate injection, USP), a potential treatment for retinitis pigmento ...